Small-molecule inhibitors of the interaction between TNF and TNFR

Future Medicinal Chemistry

Volumn 5, Issue 1, 2013, Pages 69-79

  Davis, Jessica M ^a   Colangelo, Julie ^a  

^a FAIRFIELD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [2,6 DIFLUOROPHENYL 4A,5,6,7,8,8A HEXAHYDRO 4A (4 METHOXYPHENYL) 4H BENZO[E][1,3]OXAZINE]; DNA FRAGMENT; ERYTHROSINE; INDOLE; INDOLOQUINOLIZIDINE; OXAZINE DERIVATIVE; QUINUCLIDINE; ROSE BENGAL; SAPONIN; SPD 305; SURAMIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

DRUG STRUCTURE; HUMAN; IC 50; PHOTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION;

HUMANS; MODELS, MOLECULAR; PROTEIN BINDING; RECEPTORS, TUMOR NECROSIS FACTOR; SMALL MOLECULE LIBRARIES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84871603702     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.12.192     Document Type: Review

References (74)

1. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl Acad. Sci. USA 72(9), 3666-3670 (1975).
2. Beutler B, Mahoney J, Le Trang N, Pekala P, Cerami A. Purification of cachectin, a lipoprotein lipase-suppressing hormone secreted by endotoxin-induced RAW 264.7 cells. J. Exp. Med. 161, 984-995 (1985).
3. Beutler B, Greenwald D, Hulmes JD et al. Identity of tumour necrosis factor and the macrophage-secreted factor cachectin. Nature 316, 552-554 (1985).
4. Clark IA. How TNF was recognized as a key mechanism of disease. Cytokine Growth Factor Rev. 18, 335-343 (2007).
5. Bradley Jr. TNF-mediated inflammatory disease. J. Pathol. 214(2), 149-160 (2008).
6. Aggarwal BB. Signalling pathways of the TNF superfamily: A double-edged sword. Nat. Rev. Immunol. 3(9), 745-756 (2003).
7. Tracey KJ, Fong Y, Hesse DG et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 330, 662-664 (1987).
8. Duh EJ, Maury WJ, Folks TM, Fauci AS, Rabson AB. Tumor necrosis factor a activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-kB sites in the long terminal repeat. Proc. Natl Acad. Sci. USA 86, 5974-5978 (1989).
9. Jatakanon A, Uasuf C, Maziak W, Lim S, Chung KF, Barnes PJ. Neutrophilic inflammation in severe persistent asthma. Am. J. Respir. Crit. Care Med. 160(5), 1532-1539 (1999).
10. Hotamisligil G, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-A in human obesity and insulin resistance. J. Clin. Invest. 95, 2409-2415 (1995).
11. Feldmann M, Maini RN. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat. Med. 9(10), 1245-1250 (2003).
12. Kooloos WM, de Jong DJ, Huizinga TWJ, Guchelaar H-J. Potential role of pharmacogenetics in anti-TNF treatment of rheumatoid arthritis and Crohn's disease. Drug Discov. Today 12(3-4), 125-131 (2007).
13. Ettehadi P, Greaves MW, Wallach D, Aderka D, Camp RD. Elevated tumour necrosis factor-Alpha (TNFa) biological activity in psoriatic skin lesions. Clin. Exp. Immunol. 96(1), 146-151 (1994).
14. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: A comprehensive review. Pharmacol. Therapeut. 117, 244-179 (2008).
15. Lubel JS, Testro AG, Angus PW. Hepatitis B virus reactivation following immunosuppressive therapy: Guidelines for prevention and management. Intern. Med. J. 37(10), 705-712 (2007).
16. Gómez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: A multicenter active-surveillance report. Arthritis Rheum. 48(8), 2122-2127 (2003).
17. Black RA, Rauch CT, Kozlosky CJ et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-A from cells. Nature 385, 729-733 (1997).
18. Grell M, Douni E, Wajant H et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 83(5), 793-802 (1995).
19. Horiuchi T, Mitoma H, Harashima S, Tsukamoto H, Shimoda T. Transmembrane TNF-A: Structure, function and interaction with anti-TNF agents. Rheumatology 49, 1215-1228 (2010).
20. Tansey MG, Szymkowski DE. The TNF superfamily in 2009: New pathways, new indications, and new drugs. Drug Discov. Today 14(23-24), 1082-1088 (2009).
21. Kontermann RE, Scheurich P, Pfizenmaier K. Antagonists of TNF action: Clinical experience and new developments. Expert Opin. Drug Discov. 4(3), 279-292 (2009).
22. Palladino MA, Bahjat FR, Theodorakis EA, Moldawer LL. Anti-TNF-A therapies: The next generation. Nat. Rev. Drug Discov. 2(9) 736-746 (2003).
23. Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death Differ. 10, 45-65 (2003).
24. Kollias G, Kontoyiannis D. Role of TNF/ TNFR in autoimmunity: Specific TNF receptor blockade may be advantageous to anti-TNF treatments. Cytokine Growth Factor Rev. 13(4-5), 315-321 (2002).
25. Faustman D, Davis M. TNF receptor 2 pathway: Drug target for autoimmune diseases. Nat. Rev. Drug Discov. 9, 482-493 (2010).
26. Locksley RM, Kileen N, Lenardo MJ. The TNF and TNF receptor superfamilies: Integrating mammalian biology. Cell 104(4), 487-501 (2001).
27. Eck JM, Sprang SR. The structure of tumor necrosis factor-A at 2.6 Å resolution. Implications for receptor binding. J. Biol. Chem. 264(29), 17595-17605 (1989).
28. Banner DW, D'Arcy A, Janes W et al. Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: Implications for TNF receptor activation. Cell 73(3), 431-445 (1993).
29. Chan FK-M, Chun HJ, Zheng L, Siegel RM, Bui KL, Lenardo MJ. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science 288(5475), 2351-2354 (2000).
30. Mukai Y, Nakamura T, Yoshikawa M et al. Solution of the structure of the TNFYTNFR2 complex. Sci. Signal. 3(148), ra83(2010).
31. Mukai Y, Shibata H, Nakamura T. Struture-function relationship of tumor necrosis factor (TNF) and its receptor interaction based on 3D structural analysis of fully active TNFR1- selective TNF mutant. J. Mol. Biol. 385(4), 1221-1229 (2009).
32. Loetscher H, Stueber D, Banner D, Mackay F, Lesslauer W. Human tumor necrosis factor alpha (TNF alpha) mutants with exclusive specificity for the 55-kDa or 75-kDa TNF receptors. J. Biol. Chem. 268, 26350-26357 (1993).
33. Cabal-Hierro L, Lazo PS. Signal transduction by tumor necrosis factor receptors. Cell. Signal. 24, 1297-1305 (2012).
34. de Castro Barbosa ML, Fumian MM, de Miranda ALP, Barreiro EJ, Lima LM. Therapeutic approaches for tumor necrosis factor inhibition. Braz. J. Pharm. Sci. 47(3), 427-446 (2011).
35. Fry DC. Small-molecule inhibitors of proteinYprotein interactions: how to mimic a protein partner. Curr. Pharm. Res. 18(30), 4679-4684 (2012).
36. Wilson AJ. Inhibition of proteinYprotein interactions using designed molecules. Chem. Soc. Rev. 38, 3289-3300 (2009).
37. Berg T. Modulation of proteinYprotein interactions with small organic molecules. Angew. Chem. Int. Ed. 42(22), 2462-2481 (2003).
38. Buchwald P. Small-molecule proteinYprotein interaction inhibitors: Therapeutic potential in light of molecular size, chemical space, and ligand binding efficiency considerations. IUBMB Life 62(10), 724-731 (2010).
39. Wong M, Ziring D, Korin Y et al. TNFa blockade in human diseases: Mechanisms and future directions. Clin. Immunol. 126(2), 121-136 (2008).
40. Hawking F. Suramin: With special reference to onchocerciasis. Adv. Pharmocol. Chemother. 15, 289-322 (1978).
41. LaRocca RV, Stein CA, Myers CE. Suramin: Prototype of a new generation of antitumor compounds. Cancer Cells 2(4), 106-115 (1990).
42. Small EJ, Mayer M, Marshall ME et al. Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: Results of a randomized Phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. J. Clin. Oncol. 18(7), 1440-1450 (2000).
43. Ahles TA, Herndon JE, Small EJ et al Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma. Cancer 101(10), 2202-2208 (2004).
44. McGeary RP, Bennett AJ, Tran QB, Cosgrove KL, Ross BP. Suramin: Clinical uses and structure-Activity relationships. Mini-Rev. Med. Chem. 8, 1384-1394 (2008).
45. Stein CA. Suramin: A novel antieoplastic agent with multiple potential mechanisms of action. Cancer Res. 53, 2239-2248 (1993).
46. Grazioli L, Alzani R, Ciomei M et al. Inhibitory effect of suramin on receptor binding and cytotoxic activity of tumor necrosis factor a. Int. J. Immunopharmacol. 14(4), 637-642 (1992).
47. Alzani R, Corti A, Grazioli L, Cozzi E, Chezzi P, Marcucci F. Suramin induces deoligomerization of human tumor necrosis factor alpha. J. Biol. Chem. 268(17), 12526-12529 (1993).
48. Corti A, Fassina G, Marcucci F, Barbanti E, Cassani G. Oligomeric tumour necrosis factor alpha slowly converts to inactive forms a bioactive levels. Biochem. J. 284(Pt 3), 905-910 (1992).
49. Alzani R, Cozzi E, Corti A et al Mechanism of suramin-induced deoligomerization of tumor necrosis factor a. Biochemistry 34(19), 6344-6350 (1995).
50. Mancini F, Toro CM, Mabilia M, Giannangeli M, Pinza M, Milanese C. Inhibition of tumor necrosis factor-A (TNF-A)/TNF-A receptor binding by structural analogues of suramin. Biochem. Pharmocology 58(5), 851-859 (1999).
51. He MM, Smith AS, Oslob JD et al. Small-molecule inhibition of TNF-A. Science 310(5750), 1022-1025 (2005).
52. Cunningham BC, Ultsch M, De Vos AM, Mulkerrin MG, Clauser KR, Wells JA. Dimerization of the extracellular domain of the human growth hormone receptor by a single hormone molecule. Science 254(5033), 821-825 (1991).
53. Buller F, Zhang Y, Scheuermann J, Schafer J, Bühlmann P, Neri D. Discovery of TNF inhibitors from a DNA-encoded chemical library based on Diels-Alder cycloaddition. Chem. Biol. 16(10), 1075-1086 (2009).
54. Mannocci L, Leimbacher M, Wichert M, Sheuermann Jorg, Neri Dario. 20 years of DNA-encoded chemical libraries. Chem. Commun. 47, 12747-12753 (2011).
55. Shah BA, Chib R, Gupta P et al. Saponins as novel TNF-A inhibitors: Isolation of saponins and a nor-pseudoguaianolide from Parthenium hysterophorus. Org. Biomol. Chem. 7, 3230-3235 (2009).
56. Recio MD, Just MJ, Giner RM, Manez S, Rios JL, Hostettmann K. Antiinflammatory activity of saikosaponins from Hetromorpha trifoliata. J. Nat. Prod. 58(1), 140 (1995).
57. Prabhakar U, Lipshutz D, Bartus JO et al. Characterization of cAMP-dependent inhibition of LPS-induced TNF-Alpha production by rolipram, a specific phosphodiesterase-IV (PDE-IV) inhibitor. Int. J. Immunopharmac. 16(10), 805-816 (1994).
58. Greten TF, Eigler A, Sinha B, Moeller J, Endres S. The specific type-IV phosphodiesterase inhibitor rolipram differentially regulates the proinflammatory mediators TNF-A and nitric-oxide. Int. J. Immunopharmac. 17(7), 605-610 (1995).
59. Choi H, Lee Y, Park H, Oh D-S. Discovery of the inhibitors of tumor necrosis factor alpha with structure-based virtual screening. Bioorg. Med. Chem. Lett. 20, 6195-6198 (2010).
60. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug. Deliv. Rev. 23(1-3), 3-25 (1997).
61. Basappa, Murugan S, Kavitha CV et al. A small oxazine compound as an anti-tumor agent: A novel pyranoside mimetic that binds to VEGF, HB-EGF, and TNF-A. Cancer Lett. 297, 231-243 (2010).
62. Iozzo RV, San Antonio JD. Heparan sulfate proteoglycans: heavy hitters in the angiogenesis arena. J. Clin. Invest. 108(3), 349-355 (2001).
63. Chu CL, Goerges AL, Nugent MA. Identification of common and specific growth factor binding sites in heparin sulfate proteoglycans. Biochemistry 44(36), 12203-12213 (2005).
64. Vlodavsky I, Bar-Shavit R, Ishar-Michael R, Bashkin P, Fuks Z. Extracellular sequestration and release of fibroblast growth factor: A regulatory mechanism? Trends Biochem. Sci. 16, 268-271 (1991).
65. Chan DS-H, Lee H-M, Yang F et al. Structure-based discovery of natural-product-like TNF-A inhibitors. Angew. Chem. Int. Ed. Engl. 49, 2860-2864 (2010).
66. Carter PH, Scherle PA, Muckelbauer JA et al. Photochemically enhanced binding of small molecules to the tumor necrosis factor receptor-1 inhibits the binding of TNF-A. Proc. Natl Acad. Sci. USA 98(21), 11879-11884 (2001).
67. Fu Z-Q, Harrison RW, Reed C et al. Model complexes of tumor necrosis factor-Alpha with receptor R1 and R2. Protein Eng. 8(12), 1233-1241 (1995).
68. Ganesan L, Margolles-Clark E, Song Y, Buchwald P. The food colorant erythrosine is a promiscuous proteinYprotein interaction inhibitor. Biochem. Pharmacol. 81, 810-818 (2011).
69. Wells JA, McClendon CL. Reaching for high-hanging fruit in drug discovery at proteinY protein interfaces. Nature 450, 1001-1009 (2007).
70. Wiltgen M, Tilz GP. Tumour necrosis factor and its receptor: A basic structural analysis of two counterparts. Hematology 13(4), 224-229 (2008).
71. Murali R, Cheng X, Berezov A et al. Disabling TNF receptor signaling by induced conformational perturbation of tryptophan-107. Proc. Natl Acad. Sci. USA 102(31), 10970-10975 (2005).
72. Kajiwara K, Saito A, Ogata S, Tanihara M. Synthetic peptides corresponding to ligand-binding region of death receptors, DR5, Fas, and TNFR, specifically inhibit cell death mediated by the death ligands, respectively. Biochimica et Biophysica Acta. 1699(1-2), 131-137 (2004).
73. Takasaki W, Kajino Y, Kajino K, Murali R, Greene MI. Structure-based design and characterization of exocyclic peptidomimetics that inhibit TNF alpha binding to its receptor. Nat. Biotechol. 15(12), 1266-1270 (1997).
74. Saito H, Kojima T, Takahashi M et al. A tumor necrosis factor receptor loop peptide mimic inhibits bone destruction to the same extent as anti-tumor necrosis factor monoclonal antibody in murine collagen-induced arthritis. Arthritis Rheum. 56(4), 1164-1174 (2007).